We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.
- Authors
Nakano, Yutaka; Kitago, Minoru; Matsuda, Sachiko; Nakamura, Yuki; Fujita, Yusuke; Imai, Shunichi; Shinoda, Masahiro; Yagi, Hiroshi; Abe, Yuta; Hibi, Taizo; Fujii-Nishimura, Yoko; Takeuchi, Ayano; Endo, Yutaka; Itano, Osamu; Kitagawa, Yuko
- Abstract
Background:Pancreatic ductal adenocarcinoma (PDAC) has very poor prognosis despite existing multimodal therapies. This study aimed to investigate whether KRAS mutations at codons 12/13 in cell-free DNA (cfDNA) from preoperative and postoperative sera from patients with PDAC can serve as a predictive biomarker for treatment response and outcomes after surgery.Methods:Preoperative and postoperative serum samples obtained from 45 patients with PDAC whom underwent curative pancreatectomy at our institution between January 2013 and July 2016 were retrospectively analysed. Peptide nucleic acid-directed PCR clamping was used to identify KRAS mutations in cfDNA.Results:Among the 45 patients enrolled, 11 (24.4%) and 20 (44.4%) had KRAS mutations in cfDNA from preoperative and postoperative sera, respectively. Multivariate analysis revealed that KRAS mutations in postoperative serum (hazard ratio (HR)=2.919; 95% confidence interval (CI)=1.109-5.621; P=0.027) are an independent prognostic factor for disease-free survival. Furthermore, the shift from wild-type KRAS in preoperative to mutant KRAS in postoperative cfDNA (HR=9.419; 95% Cl=2.015-44.036; P=0.004) was an independent prognostic factor for overall survival.Conclusions:Changes in KRAS mutation status between preoperative and postoperative cfDNA may be a useful predictive biomarker for survival and treatment response.
- Publication
British Journal of Cancer, 2018, Vol 118, Issue 5, p662
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/bjc.2017.479